MAK Capital

MAK Capital outperform competitors over the long term by opportunistically investing in a fundamental

Craig Nemiroff

Managing Director

2 past transactions

MARABio

Series A in 2024
MARABio is a biotechnology company focused on the detection and prevention of severe forms of Autism Spectrum Disorder (ASD). The firm specializes in maternal autoantibody-related autism testing, which assesses the risk of ASD by identifying a unique cluster of antibodies in mothers that target proteins in the developing brains of their children. This licensed technology allows for early intervention, enabling mothers to initiate targeted behavioral therapies if their children show signs of developmental delay. By providing critical insights into the maternal health factors associated with autism, MARABio aims to improve outcomes for children at risk for ASD.

Noveome Biotherapeutics

Series E in 2023
Noveome Biotherapeutics, Inc. is a clinical-stage biotherapeutics company based in Pittsburgh, Pennsylvania, founded in 2000. The company develops innovative biotherapeutic products aimed at addressing complex biological processes, particularly in the repair of inflamed or damaged tissues. Its lead product, ST266, is designed to modulate inflammation, enhance wound healing, promote bone restoration, restore nerve function, and facilitate cellular regeneration. Noveome's therapies leverage a range of biologic components at physiological concentrations that work synergistically to deliver anti-inflammatory, neuroprotective, and vascular integrity-preserving effects, providing healthcare providers with advanced treatment options for various complex diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.